Lars Bastiaanse

Rejuvenate Biomed is a clinical-stage platform and Belgian pipeline company founded in 2017 by Ann Belià « n. The company is committed to discovering and developing innovative combination drugs that can safely delay the onset of various age-related diseases. Rejuvenate Biomed has developed two proprietary drug discovery platforms, in silico combinagetm and in vivo celegagetm, to efficiently screen molecule libraries across a wide spectrum of age-related pathways. RJX-01, one of their drugs, is ready for a phase 2b clinical trial in sarcopenia, a musculoskeletal disease. The company is based on the Health Campus Limburg in Heusden-Zolder, BE. Ann Beliën has been the CEO since incorporation.

ANeuroTech is a Belgian mental health company that specializes in developing innovative treatments with minimal or no side effects. ANeuroTech is located in Belgium. The private company's lead asset, ant-01, is an adjunctive anti-depression drug that has shown positive results in late-stage clinical trials. The drug is a low-dose of an existing substance, pipamperone dihydrochloride, and has an excellent safety profile. ANeuroTech plans to begin a pivotal phase iiib clinical trial of ant-01 as an adjunctive anti-depression drug for major depressive disorder (MDD) in 2023. The company was founded by CEO Dr. Erik Buntinx, an experienced clinician and key opinion leader in the field.

ANeuroTech is a Belgian mental health company that specializes in developing innovative treatments with minimal or no side effects. ANeuroTech is located in Belgium. The private company's lead asset, ant-01, is an adjunctive anti-depression drug that has shown positive results in late-stage clinical trials. The drug is a low-dose of an existing substance, pipamperone dihydrochloride, and has an excellent safety profile. ANeuroTech plans to begin a pivotal phase iiib clinical trial of ant-01 as an adjunctive anti-depression drug for major depressive disorder (MDD) in 2023. The company was founded by CEO Dr. Erik Buntinx, an experienced clinician and key opinion leader in the field.

Rejuvenate Biomed is a clinical-stage platform and Belgian pipeline company founded in 2017 by Ann Belià « n. The company is committed to discovering and developing innovative combination drugs that can safely delay the onset of various age-related diseases. Rejuvenate Biomed has developed two proprietary drug discovery platforms, in silico combinagetm and in vivo celegagetm, to efficiently screen molecule libraries across a wide spectrum of age-related pathways. RJX-01, one of their drugs, is ready for a phase 2b clinical trial in sarcopenia, a musculoskeletal disease. The company is based on the Health Campus Limburg in Heusden-Zolder, BE. Ann Beliën has been the CEO since incorporation.

Rejuvenate Biomed is a clinical-stage platform and Belgian pipeline company founded in 2017 by Ann Belià « n. The company is committed to discovering and developing innovative combination drugs that can safely delay the onset of various age-related diseases. Rejuvenate Biomed has developed two proprietary drug discovery platforms, in silico combinagetm and in vivo celegagetm, to efficiently screen molecule libraries across a wide spectrum of age-related pathways. RJX-01, one of their drugs, is ready for a phase 2b clinical trial in sarcopenia, a musculoskeletal disease. The company is based on the Health Campus Limburg in Heusden-Zolder, BE. Ann Beliën has been the CEO since incorporation.